Marmar C R, Schoenfeld F, Weiss D S, Metzler T, Zatzick D, Wu R, Smiga S, Tecott L, Neylan T
Department of Psychiatry, University of California San Francisco, USA.
J Clin Psychiatry. 1996;57 Suppl 8:66-70; discussion 71-2.
A 10-week open-label trial of fluvoxamine was conducted for male Vietnam combat veterans with chronic PTSD. Subjects were excluded if they met full current criteria for panic disorder or agoraphobia, and lifetime criteria for psychosis, bipolar disorder, or organic mental syndrome. Repeated MANOVA was performed to determine change over time. Fluvoxamine was well tolerated; side effects were observed primarily early in treatment with headache, insomnia, sedation, and gastrointestinal distress being most frequent. Fluvoxamine was effective for treating the core intrusion, avoidance, and arousal symptoms of PTSD. Large treatment effects were seen by 4-6 weeks, and maintained at 10 weeks. The magnitude of change was greater than has been previously reported for antidepressant treatment of male Vietnam combat veterans with PTSD.
针对患有慢性创伤后应激障碍（PTSD）的越南男性退伍军人开展了一项为期10周的氟伏沙明开放标签试验。如果受试者符合当前惊恐障碍或广场恐惧症的全部标准，以及精神病、双相情感障碍或器质性精神综合征的终生标准，则将其排除。进行重复多变量方差分析以确定随时间的变化。氟伏沙明耐受性良好；副作用主要在治疗早期观察到，最常见的是头痛、失眠、镇静和胃肠道不适。氟伏沙明对治疗PTSD的核心侵入性、回避性和唤醒症状有效。在4至6周时可见显著治疗效果，并在10周时维持。变化幅度大于先前报道的抗抑郁药治疗患有PTSD的越南男性退伍军人的效果。
